IJCRAR is now DOI (CrossRef) registered Research Journal. The DOIs are assigned to all published IJCRAR Articles.

Abstract                 Volume:5  Issue-3  Year-2017          Original Research Articles


Online ISSN : 2347 - 3215
Issues : 12 per year
Publisher : Excellent Publishers
Email : editorijcret@gmail.com

Electrical Pulse-Mediated Veliparib for Effective Treatment of Triple Negative Breast Cancer: An in vitro Model Study
Lakshya Mittal1, Vishak Raman2, Ignacio G. Camarillo2,3 and Raji Sundararajan1*
1School of Engineering Technology, Purdue University, Indiana, USA
2Department of Biological Sciences, Purdue University, Indiana, USA
3Purdue University Center for Cancer Research, Indiana, USA
*Corresponding author
Abstract:

Use of Poly (ADP-ribose) polymerase (PARP) inhibitors has received major attention as therapeutic agents for the treatment of breast cancers with or without mutations in BRCA1 or BRCA2. Thus, it can be effectively used for triple negative breast cancer (TNBC), which lacks the conventional receptors that many chemo drugs attack. Veliparib, a PARP agent is used as 2nd line of treatment along with platinum compounds. It is of practical interest to study the efficacy of Veliparib alone as an anti-cancer drug for TNBC. Towards this, in this research, we studied the efficacy of Veliparib on MDA-MB-231, human triple negative breast cancer cells.  A concentration of 330µM was used for this purpose. In addition, to enhance the uptake of Veliparib against the plasma membranes of the cells, electroporation technique is used, which involves the local application of electrical pulses to open pores, which enables easy drug passage across the cell membranes. Thus, the objective of this study is to identify the potential of Veliparib and Electroporation as an alternate combinational therapy for TNBCs. Electrical pulses of high intensity, low duration 1200V/cm, 100μs, 8 pulses and low intensity high duration 500V/cm, 20ms, 8 pulses are used in this study. Cell viabilities were measured immediately, as well as after 24, 48 and 72 hours of treatment. The results indicate cell viabilities of 70% immediately after Veliparib+electrical pulses treatment, compared to 94% with drug only, indicating the potential of the synergy of electrical pulses+Veliparib. The viabilities were lower by 11 to 13 times after 72 hours. This promising treatment is transferrable to clinical practice.

Keywords: Triple Negative Breast Cancer, Veliparib, PARP inhibitors, Electrochemotherapy, Electrical Pulses
Download this article as Download

How to cite this article:

Lakshya Mittal, Vishak Raman, Ignacio Camarillo and Raji Sundararajan. 2017. Electrical Pulse-Mediated Veliparib for the Treatment of Triple Negative Breast Cancer: An in vitro Model Study.Int.J.Curr.Res.Aca.Rev. 5(3): 53-64
doi: https://doi.org/10.20546/ijcrar.2017.503.009